Company intelligence / Profile preview
Axolotl Biologix
- Ownership
- Private
- Development stage
- Other
Overview
Axolotl Biologix develops and commercializes advanced human amnion graft products used in wound care and tissue repair. Their lead commercial product line, DualGraft, uses placental tissue to create a structural membrane that covers wounds and supports healing. They are also developing an investigational injectable therapy derived from cultured placental cells aimed at orthopedic indications like ankle arthritis. The company’s products are supported by peer-reviewed research and ongoing clinical trials.
- Therapeutic areas
- DermatologyRheumatology
- Modalities
- Human amnion grafts (tissue-based products)Cell culture-derived growth factor solutions
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Axolotl Biologix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axolotl Biologix.